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Abstract
Lung cancer continues to be the most common neoplasia and represents the 
leading cause of cancer-related death in the world. Nonetheless, contrary to 
expected projections, the decrease in incidence expected by decrease in tobacco 
exposure has been partially halted due to an increasing amount of lung cancer 
cases in nonsmokers, particularly in female patients. This led to the development 
of new hypotheses in terms of lung cancer etiology, including the involvement 
of oncogenic viruses such as the human papillomavirus (HPV). HPV role in 
the pathophysiology of lung cancer, including adenocarcinoma and squamous 
cell carcinoma, is currently under research. Exposure to HPV, and the resulting 
infection, can occur in several possible ways, including sexual transmission and 
airborne fomites. Main pathogenic occurrences include alterations in inhibition of 
p53 and retinoblastoma. This chapter presents the current evidence as to the role 
of HPV in the development of lung cancer, methods to establish HPV infection, 
and also explores the role of predisposing factors, as well as immunological and 
inflammatory factors in nonsmokers. Additionally, the role of other molecular 
factors, such as EGFR, interleukins 6 and 10, and others, is discussed. Finally, 
future perspectives in this new paradigm of lung cancer in nonsmokers are 
broadly reviewed.
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1. Introduction
Lung cancer is the most common cancer in the world. In 2012, 1.8 million new 
cases were diagnosed and 1.6 million people died as a consequence of this disease 
[1]. It is one of the top 10 leading causes of death worldwide [2]. About 90% of lung 
cancer cases in men and 75% in women in the United States and Europe are caused by 
tobacco smoke [3, 4]. An important proportion of lung cancer cases presents in non-
smokers, as shown in several reports. In the Caucasian population, the rate of non-
small cell lung cancer (NSCLC) in non-smokers is 10% for men and 20% for women, 
while for Asian populations the rate reached 30–40% [5, 6]. In the United States, the 
overall lung cancer incidence rates and mortality have been declining for the past two 
decades, and the reduction in both of these parameters has been more prominent in 
men than in women, a trend that likely reflects the decrease in smoking rates in the 
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male population [7]. Interestingly, in developed countries, lung cancer incidence has 
been gradually increasing for non-smokers [8–10]. In Asian countries, the situation is 
similar; lung cancer incidence and mortality have been increasing despite the imple-
mentation of successful anti-smoking campaigns [11, 12].
Among the histologic subtypes of NSCLC, squamous cell lung cancer (SCC) is 
more common in men (44% cases in men vs. 25% in women) and adenocarcinoma 
(ADC) is more common in women (28% cases in men and 42% in women). SCC 
and small cell lung cancers (SCLC) are more closely associated with smoking, in 
contrast to ADC that is most commonly found in non-smokers [13]. In fact, the 
calculated histological distribution of lung cancer among smokers and non-smokers 
in 17 different studies has shown that 53% of the cases in smokers and 19% in 
non-smokers are SCC while 62% in non-smokers and 18% in smokers are ADC [14]. 
Furthermore, ADC in non-smokers appears to have a less complex histology with a 
higher presence of targetable driver mutations, particularly EGFR, Her2 as well as 
ALK and ROS translocations [15, 16].
The differences in epidemiology, genetic profile, and survival outcomes of lung 
cancer in non-smokers have made it clear that this malignancy is a separate entity 
from lung cancer in smokers [17]. Over the last decades, the investigation of the 
preventable risk factors associated with lung cancer in non-smokers has gained 
much attention. Of interest, human papillomavirus (HPV) has been reported in 
Figure 1. 
Forest plot of random effects model stratified by study design. Individual study OR and grouped ORs sub 
(reproduced with authorization from Ref. [24].
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lung cancer tissues from Western and Eastern countries, being types 18 and 16 
the most common pathogenic species [18–21]. Likewise, recent studies have dem-
onstrated a significantly increased risk of acquiring lung cancer in non-smokers 
who are exposed to HPV infection (OR 5.32; 95% CI 1.75–16.17) [22, 23]. Figure 1 
depicts a meta-analysis of recent studies evaluating the association between HPV 
infection and lung cancer.
Importantly, the public health impact of these recent findings has been recently 
explored, since vaccination against HPV could represent an efficacious measure to 
prevent lung cancer. Additionally, the timely detection of HPV in the respiratory 
tract could warrant a method for early diagnosis of lung cancer, particularly in the 
non-smoker population [25, 26].
2.  Immune and inflammation markers in lung cancer among never 
smokers
Multiple studies have shown an increased incidence of non-smoker lung 
cancer in females [3, 9, 10, 27–30]. After analyzing a cohort of 975 patients in 
Singapore, Yano et al. identified that non-smoker lung cancer patients presented 
at a younger age and with an earlier stage at diagnosis than their smoker coun-
terparts [10]. The most important risk factors for lung cancer in non-smokers 
are second-hand smoke, indoor air pollution, occupational exposures, genetic 
susceptibility, family history, estrogen levels, HPV infection, and pre-existing 
respiratory diseases [15].
Respiratory diseases elicit a deleterious chronic inflammatory response in 
lung tissue, which in turn causes an increased rate of cell division leading to an 
augmented risk of DNA damage [31]. Additionally, inflammation stimulates anti-
apoptotic signal activation and angiogenesis further promoting tumorigenesis  
[32, 33]. Previous studies have also suggested an important role for lung diseases 
in the development of lung cancer, even when not associated with tobacco use. In 
2012, Brenner et al. carried out an extensive analysis from 17 studies and identified 
that a history of emphysema, pneumonia, and tuberculosis elevated the risk for 
lung cancer development among non-smokers [34]. Likewise, other case-control 
studies across various populations have concluded that a history of respiratory 
diseases, including chronic obstructive pulmonary disease (COPD), asthma, pneu-
monia, and tuberculosis, would increase the risk of developing lung cancer [35–40]. 
A systematic review demonstrated that pre-existing tuberculosis increased lung 
cancer risk in non-smokers (RR 1.78, 95% CI 1.42–2.23); interestingly, the increased 
risk was only associated with ADC histology, while SCC and SCLC showed no 
association [41].
Due to the association between respiratory diseases and lung cancer among 
non-smokers, inflammatory pathways and markers have been the focus of much 
interest in recent years and hence have been widely studied. A case-control study 
nested within three prospective cohort studies carried out in Australia and Sweden 
identified a higher lung cancer risk for participants who had elevated concentra-
tions of interleukin (IL)-6 and IL-8. These associations were stronger for former 
smokers (smoking cessation at least 10 years before study was performed) than 
for current smokers, both for IL-6 and IL-8; however, these associations were not 
observed in never-smoker patients [42]. Other inflammatory markers have been 
found to be significantly associated with lung cancer risk. In a previous case-control 
study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening trial 
(PLCO), 11 markers of importance were identified. Interestingly, nine of these 
markers were significantly associated with lung cancer among non-smokers, which 
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included the epithelial neutrophil-activating peptide 78 (ENA-78/CXCL5) and 
IL-7, and also associated with lung cancer overall, and others not associated with 
lung cancer overall, which included human granulocyte chemotactic protein-2 
(GCP2/CXCL6), granulocyte colony stimulating factor (G-CSF), IL-6, macrophage 
inflammatory protein 1B, 2 and 4 (MIP-1B/CCL4, MCP-2/CCL8, MCP-4/CCL13), 
and stromal cell derived factor-1 (SDF-1 A-B/CXCL12) [43]. Two years later, the 
PLCO trial was nested to its replication in a case-control study. Both of the nested 
case-control trials demonstrated that circulating levels of C-reactive protein (CRP), 
serum amyloid A (SAA), soluble tumor necrosis factor receptor 2 (sTNFRII), and 
monokine induced by gamma interferon (CXCL9/MIG) were associated with lung 
cancer risk [43, 44]. These associations were limited to smokers, and the study 
was considered to be underpowered to evaluate associations among non-smokers 
[44]. Finally, a nested case-control study carried out within the Shanghai Women’s 
Health Study evaluated 61 inflammatory markers among non-smoker Chinese 
women. Nine markers were statistically significantly associated with lung cancer: 
soluble IL-6 receptor (sIL6R) and chemokine ligand 2/monocyte chemotactic 
protein 2 (CCL2/MCP-1) were associated with an increased risk of lung cancer, 
while IL-21, chemokine (C-X3-C motif) ligand 1/fractalkine (CX3CL1/fractalkine), 
soluble vascular endothelial growth factor receptor 2 (sVEGFR2) and sTNFRII and 
CRP were associated with a decreased risk. Interestingly sIL-6R was associated with 
an increased lung cancer risk even 7.5 years prior to diagnosis. The results of this 
study further support our current knowledge in terms of the role of inflammation 
and immune response on the development of lung cancer among the female non-
smoker population.
3. HPV transmission in lung cancer
Since the respiratory tract is composed of two different epitheliums, it contains 
various squamous columnar junctions (SCJ). In the bronchi, the SCJ may occur 
naturally or most commonly as squamous metaplasia (SQM) secondary to ciga-
rette smoking [45]. The SQM process initiates with the activation and posterior 
hyperproliferation of the SQM quiescent basal cells present in the pseudostratified 
epithelium. As a consequence, the epithelial cells begin to show a squamous cell 
differentiation, given by the expression of squamous epithelial cytokeratins and cell 
adhesion molecule SQM1. Finally, cells express involucrin, a protein which indicates 
that the cells are in a terminal differentiation stage [46–52]. The biochemical and 
metabolic changes that SQM induces make the bronchial epithelium susceptible to 
HPV infection. Hence, the multiple foci of SQM in the bronchi are analogous to the 
transformation zone of the uterine cervix, as both work as the point of entry for 
HPV [53, 54].
To date, there are three hypotheses regarding HPV infection and transmission 
into the pulmonary tissue [24, 55]. The first one states that the HPV infection occurs 
in the reproductive system (male or female) and then hematogenously transmitted 
to the lung tissue. A study reports that approximately 80% of female HPV-positive 
lung cancer patients also have cervical intraepithelial neoplasia [56]. Peripheral 
blood cells (B cells, dendritic cells, NK cells, and neutrophils) on healthy men have 
been shown to be infected by high- and low-risk HPV [57]. Furthermore, Bodaghi 
et al. identified HPV types 16 and 18 on peripheral blood from healthy transfusion 
donors [58]. Since the lung is a highly vascularized tissue, this makes it susceptible 
to capture the virus and eventually develop the tumor. More evidence to support 
this hypothesis is the high prevalence of HPV DNA in peripheral blood samples 
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seen in NSCLC patients [25]. These findings have led some authors to suggest that 
these peripheral blood cells can be a viral reservoir for the infection of other organs 
and even contribute to viral spread in a sexual contact-independent manner [55]. 
Another hypothesis refers to oral-genital HPV infection that causes transmission 
through the throat into the lung. HPV infection may be propagated either through 
oral-oral contact or genital to oral contact. A survey that followed 222 men and their 
female patterns showed an infection rate in men of 7.2% with the majority of their 
female partners having either cervical or oral HPV infection. And finally, a third 
hypothesis is that HPV may be transmitted as an airborne disease. Carpagnano et al. 
reported the presence of HPV DNA in exhaled breath condensate of lung cancer 
patients, hence proposing that HPV transmission can occur through inhalation [59]. 
These hypotheses are summarized in Figure 2.
4. Possible molecular mechanisms of HPV-induced lung carcinogenesis
HPV initially interacts with cellular receptors and infects the basal lamina, trans-
ferring its viral genomes to the nucleus [60]. These events are followed by an initial 
phase of genome amplification and afterwards by a steady maintenance of the viral 
episome at low copy number [61, 62], particularly around 200 copies per cell, based 
on the study of episomal cell lines derived from cervical lesions [63]. The replication 
process requires the hijacking of the of the Retinoblastoma family of proteins (RB, 
p108 and p130), which regulate cell proliferation, as well as the inhibition of p53, 
which disrupts apoptosis [64]. The carcinogenic potential comes from the presence of 
the genes E6 and E7 in the HPV genome, especially in serotypes 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, and 59. The E6 protein is composed of roughly 150 amino acids and 
has the ability to interact with many targets due to its structure containing two zinc 
fingers built by two pairs of CXX motifs [65]. The main target of this protein is p53. 
After binding with E3 ubiquitin ligase UBE3A/E6AP (E6-associated protein), the E6/
E6AP complex marks p53 for proteasome-dependent degradation. E6 is also involved 
in other steps of oncogenesis including guarantying survival of the infected cells and 
offering evasion of the infected cells from the immune system. This protein has in 
turn the ability to stimulate interleukin-10 (IL10) expression, a cytokine responsible 
for immunomodulation and anti-inflammatory effects. Among its effects, IL10 has 
the ability to induce autocrine and paracrine immunologic tolerance due to activa-
tion of T helper 2 and T regulatory lymphocytes, inhibition of pro-inflammatory 
cytokines, and downregulation of the MHC classes I and II, arresting DC maturation 
Figure 2. 
Possible transmission pathways of HPV infection.
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and downregulating intercellular adhesion molecules and co-stimulating mediators. 
Additionally, IL10 has been shown to promote early E6 and E7 expression, consoli-
dating a vicious cycle [66]. Other interleukins such as IL6 have been shown to be both 
a stimulator and an inhibitor of cell proliferation, depending on the cell line exposed. 
Through a complex process in which E6 causes STAT3 activation and IL6 expres-
sion, the cancer-associated fibroblast cells, present in the tumor microenvironment, 
suffer from IL6-induced and p16-mediated senescence. This phenomenon of adjacent 
cell dysfunction has been shown to promote neoplastic growth due to paracrine 
stimulation, chronic inflammation, and loss of oncolytic countermeasures [67]. 
Furthermore, IL6 has the ability to induce antiapoptotic Mcl-1 expression in HPV-
infected lung cancer cells [68]. Mcl-1, member of the BCL-2 gene family is respon-
sible, together with the Bcl-2 protein, for the apoptotic response of the mitochondria. 
Mcl-1 inhibits apoptosis by capturing BH3 and thus inhibiting Bax/Bcl-xl transloca-
tion, crucial steps in propagating an apoptotic signal in the cell [69]. Similarly, Bcl-2 
offers a comparable Bax translocation inhibition, thus offering a strong antiapoptotic 
signal [70]. All in all, E6-activated and Il6-mediated BCL2 family modulation seems 
to be responsible for contributing to apoptosis inhibition and immortalization of 
HPV-infected cells. Other mechanisms of E6-induced immortalization include the 
expression of cIAP2, which is considered to be a very potent antiapoptotic factor in 
these cells by being the upstream inhibitor of caspase 3 activity. This hypothesis was 
validated in a study of induction of apoptosis in HeLa cells transfected with E6 and 
E7 proteins by knockdown of this molecule. E6 in turn causes the binding of p52 to 
NF-κB leading to an upregulation in the expression of cIAP [71, 72]. Additionally, 
this molecule lays as a downstream step in EGFR signaling, and its expression has 
also been strongly correlated with the presence of EGFR mutations [73]. One pos-
sible hypothesis to explain this phenomenon relates to the E6 inhibition of p53. 
Inactivation of this protein in turn leads to the loss of function in the MMR pathway, 
especially in MLH1 and MSH2, thus causing an increase in reactive oxygen species, 
which also strongly correlates with exon 19 EGFR mutations in lung cancer [74]. 
Finally, matrix metalloproteinases (MMP) seem to be also influenced by E6 interac-
tions. These enzymes are responsible for degradation of the extracellular matrix, 
process required for cell migration and development of metastasis. MT1-MMP, 
MMP-2, and MMP-9 are the main members of this family that were upregulated by 
the expression of this oncogene [75], possibly by the induction of microRNAs [76].
E7, on the other hand, is responsible for binding and degrading pRb, p105, 
p107, and p130, especially in the upper epithelial layers. Additionally, E7 causes 
genome instability by deregulating the centrosome cycle [60]. Additionally, occurs 
the induction of the aryl hydrocarbon receptor signaling, a transcription factor 
involved in proliferation, differentiation, and apoptosis. Members of this fam-
ily and inhibitors of cyclin-dependent kinases p16 and p21 have been proven to 
bind to E7 increasing pRb phosphorylation and promoting furthermore cell cycle 
deregulation [77]. Other activities can also be impaired by E7, such as epigenetic cell 
function. This molecule has the capacity to displace histone deacetylases, specially 
HDAC 1, 4, and 7 blocking their binding sites to the HIF-1α promoter regions and 
leading to an upregulation of its expression. This, in turn, is considered a key step in 
angiogenesis and thus strongly contributes to tumor growth [78].
5. HPV gene expression and detection in lung tissue
The relation between HPV and lung cancer was postulated since the decade of 
the 1970s. In 1975, Roglic et al., followed by Rubel and Reynolds in 1979, observed 
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koilocytosis, a classical pattern in HPV infection, in sputum samples from benign 
bronchial lesions [79, 80]. Simultaneously, Syrjanen described that the epithelial 
changes seen in bronchial carcinoma closely resembled HPV-induced genital lesions 
[81]. Afterwards, several epidemiological data, particularly in non-smoking lung 
cancer patients, firmly established the relationship between HPV infection and 
development of lung cancer.
Although several studies showed the presence of oncogenic HPV in lung cancer 
tissue, demonstrating a causal role is necessary. Taking into account that integra-
tion of HPV DNA within the host is the critical point for oncogenic transforma-
tion, demonstration of the HPV DNA presence in lung cancer DNA cells is the 
main goal.
Cheng et al. demonstrated that HPV DNA was integrated into lung cancer DNA 
cells but not in the adjacent non-tumor cells and also demonstrated that HPV (+) 
lung cancer patients were predominantly non-smoking females, suggesting a role 
of HPV infection in the development of lung cancer in non-smokers (OR 10.12, 
CI 95%: 3.88–26.38 for non-smoking females), and it was one of the first proofs of 
concept of this causative role [82]. In this study, HPV DNA of high-risk serotypes 
16 and 18 was determined by nested PCR and in situ hybridization (ISH). Taking 
this under consideration, PCR is an ideal method for determining HPV-Host DNA 
integration. The presence of HPV infection can be assessed through different 
methods, including the use of lung tissue samples (Frozen, Fresh or Formalin fixed 
and paraffin embedded tissue) but also serological samples (using techniques such 
as Bead-based multiplex serology method or Multiplex liquid bead microarray 
antibody assay) [24]. However, one must consider that serologic analysis is usu-
ally limited by the low amount of HPV circulating in the bloodstream and also by 
the low sensitivity and specificity of serological detection techniques; therefore, 
lung tissue is usually better accepted. In a previous meta-analysis, Xiong et al. [24] 
evaluated the association between HPV and lung cancer in over 6000 lung cancer 
patients and 24,000 HPV-exposed individuals. The results showed an association 
between lung cancer and HPV (OR 3.64; 95% CI: 2.60–5.08), with most studies 
(75% [28/37]) using polymerase chain reaction (PCR) analysis in lung cancer tissue 
for HPV detection. The sensitivity and false-positive rate of PCR is higher than 
with other methods, including in situ hybridization, Southern blot, dot blot, and 
sequencing [83, 84].
5.1 HPV detection and genotyping
In brief, DNA is extracted from lung cancer tissue and then different PCR 
methods can be used. One of the most common PCR methods used for HPV 
detection and genotyping is INNO-LiPA Genotyping Extra assay (Innogenetics 
N.V., Ghent, Belgium) [84]. This assay can detect 18 high-risk types using a reverse 
hybridization line probe (16, 18, 26, 31, 33, 35, 39, 45, 51–53, 56, 58, 59, 66, 68, 73, 
82), 7 low-risk types (6, 11, 40, 43, 44, 54, 70), and some additional types (69, 71, 
74). The assay also includes negative and positive controls (HPV6), as well as an 
internal control (HLA-DPB1 gene), to confirm DNA quality and the absence of 
PCR inhibitors. The results of trials conducted using each technique are summa-
rized in Table 1.
In conclusion, the association between HPV infection and lung cancer should 
demonstrate the integration between HPV DNA and lung tumor cells DNA. The 
method usually performed for this assessment is PCR, and different techniques for 
genotyping have been used, mainly methodologies that include detection of high-
risk serotypes but also low risk serotypes.
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Author, year Country Method HPV 
types
Sample 
type
Cases 
(n/N)
Controls 
(n/N)
Béjui-Thivolet, 
1990
France ISH 6, 11, 16, 
18
Tissue 6/33 0/10
Li, 1995 China PCR, DB 16, 18 Tissue 16/50 0/22
Fong, 1995 Australia PCR 6, 11, 16, 
18, 31, 
33, 52b, 
58
Tissue 2/104 0/104
Yang, 1998 China PCR 6/11, 16, 
31/33
Tissue 13/50 3/30
Niyaz, 2000 China PCR 16, 18 Tissue 44/110 1/40
Cheng, 2001 China PCR, ISH 16, 18 Tissue 77/141 16/60
Chiou, 2003 China PCR 16, 18 Blood 71/149 22/174
Cheng, 2004 China PCR, ISH 6, 11 Tissue 40/141 1/60
Jain, 2005 India PCR 16, 18 Tissue 
(case)
Blood 
(control)
2/40 0/40
Ciotti, 2006 Italy PCR, 
sequencing
16, 18, 
31
Tissue 8/38 0/38
Fei, 2006 China ISH 16, 18 Tissue 23/73 2/34
Giuliani, 2007 Italy PCR, 
reverse blot 
hybridization, 
sequencing
— Tissue 10/78 0/78
Nadji, 2007 Iran PCR, 
sequencing
— Tissue 33/129 8/89
Buyru, 2008 Turkey PCR, SB 16, 18 Blood 1/65 0/87
Wang, 2008 China PCR, ISH, 
IHC
16, 18 Tissue 138/313 4/96
Yu, 2009 China PCR 25 types Tissue 43/109 16/71
Xu, 2009 China ISH 16/18 Tissue 32/44 0/15
Krikelis, 2010 Greece PCR 16 Tissue, 
BW
36/58 11/16
Wang, 2010 China PCR 16, 18 Tissue 18/45 0/16
Joh, 2010 USA PCR, 
sequencing
— Tissue 5/30 0/21
Carpagnano, 
2011
Italy PCR, 
sequencing, 
INFINITI 
HPV-QUAD 
assay
16, 18, 
30, 31, 
33, 45, 
35/68, 
39/56, 
58/52, 
59/51, 
6/11
Tissue, 
BW, EBC
12/89 0/68
Galvan, 2012 Italy, UK PCR,DB 35 types Tissue 0/100 0/100
Gatta, 2012 Italy PCR 16, 18, 
33, 35, 
52, 58
Tissue 2/50 1/23
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6. HPV in lung cancer clinical information and perspective
There are at least three postulated ways for HPV virus to reach the tracheobron-
chial tract and cause epithelial transformation and malignancy: (1) cervical to lung 
transmission, (2) from an infected reproductive system to the mouth, throat, and 
finally lungs, and (3) airborne transmission. All of these have been supported by 
solid epidemiological data [56, 59, 85, 86]. Once HPV reaches the tracheobronchial 
epithelium, several molecular and cytological changes can occur as consequence of 
proteins E6 and E7 from HPV. These oncogene proteins can regulate expression of 
Author, year Country Method HPV 
types
Sample 
type
Cases 
(n/N)
Controls 
(n/N)
Yu, 2013 China PCR, 
reverse blot 
hybridization, 
SB
25 types Tissue 75/170 21/91
Anantharaman, 
2014
7 
European 
countries
BMSM 6, 11, 16, 
18, 31
Blood 791/ 
1634
991/2729
Sagerup, 2014 Norway PCR 15 types Tissue 13/334 0/13
Sarchianaki, 
2014
Greece PCR, 
genotyping
37 types Tissue 19/ 
100
0/16
Yu, 2015 China PCR L1, 16, 
18
Tissue 100/ 
180
8/110
Fan, 2016 China ICC 16 Pe 42/95 1/55
Gupta, 2016 India PCR 16, 18, 
31, 33, 
45
FNAC, 
tissue
5/73 0/75
Lu, 2016 China PCR 16, 18 Tissue 33/72 2/54
Robinson, 2016 USA Microarray, 
oncovirus 
panel, 
genotyping 
PCR
28 types Tissue 15/57 1/10
Xiong, 2016 China PCR, 
reverse blot 
hybridization
21 types Tissue 7/83 6/83
Simen, 2010 Finland ELISA 16, 18 Serum 67/311 220/930
Anantharaman, 
2014
10 
European 
countries
BMSM 6, 11, 16, 
18, 31
Blood 604/ 
1449
601/1599
Colombara, 
2015
USA LBMA 6, 11, 16, 
18, 31, 
33, 52, 
58
Serum 4/200 15/200
Colombara, 
2016
China LBMA 6, 11, 16, 
18, 31, 
33, 52, 
58
Serum 8/183 8/2
Table 1. 
Summary of reported trials conducted using each HPV detection and genotyping technique.
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several target genes and proteins, which derives in promoted lung cell proliferation, 
angiogenesis, and cell immortalization. Among the genes and proteins affected are 
p53, pRb, HIF-1α, VEGF, IL-6, IL-10, Mcl-1, Bcl-2, cIAP-2, EGFR, FHIT, hTERT, 
HER-2, ALK, ROS1, and AhR [55, 87–90]. Evidence which supports the association 
between HPV infection and lung cancer continues to grow, but debate will likely 
continue due to heterogeneous methodologies for HPV detection in lung tissue. At 
least eight systematic reviews and meta-analysis have consistently found that HPV 
infection is a risk factor for lung cancer [22–24, 84, 91–94]. One of them included 
longitudinal studies: a nested case-control and a cohort study with high causality 
[24]. According to subgroup analyses from several trials, the HPV infection con-
stitutes a risk for lung cancer, especially in non-smokers, similar to the findings in 
head and neck cancers, females and Asian race [22, 24, 82]. Additionally consider-
ing HPV affinity to squamous cells, HPV infection constitutes a risk for squamous 
cell lung cancer; however, other histologic subtypes including ADC and SCLC have 
also been related to HPV infection [23, 24, 94].
HPV serotypes 16 and 18, known as high-risk serotypes, are mainly associated 
with lung cancer risk, though low-risk serotypes are believed to cause benign, 
non-malignant, lesions [23, 24, 95]. However, this relationship has not been fully 
studied, and other serotypes including HPV 11 and HPV 31 have a less clear role in 
terms of lung cancer association. Currently available vaccines against HPV could 
theoretically prevent lung cancer development; however, this important issue 
has seldom been explored and more research is needed to draw robust conclu-
sions. HPV status modifies treatment modalities and prognosis in head and neck 
cancers. Further research is necessary to determine whether lung cancer treat-
ment should change according to HPV infection status. HPV coinfection in lung 
cancer favors the inclusion of E5 oncoprotein, which alters the mitogenic signaling 
downstream of Ras, EGFR, and PKC, as well as the constitutive activation of AP-1, 
which through c-jun may result in cell survival [96]. In the same way, E6 HPV 
protein blocks p53 activation causing an inhibition of p21 action, upregulating the 
expression of EGFR and inhibiting apoptosis by activating cIAP28. Additionally, 
the inclusion of the E7 protein leads to the downregulation of p16INK4 by 
hypermethylation and migration of tumor-infiltrating lymphocytes (TILs) [97]. 
Recently, Cheng et al. have found that HPV infection increases tumor activity 
via hypermethylation of the XRCC3 and XRCC5, an event that generates induced 
DNA [98]. In parallel, Zhang et al. proposed that inflammation related to HPV 
lung cancer is induced by increasing levels of HIF, VEGF and [90]. We previously 
reported a high HPV positivity rate in Hispanic patients suffering lung ADC; in 
addition, we described that presence of viral DNA leads to a better prognosis in 
EGFR and KRAS—mutated lung ADC and increases the expression of PDL1 [99]. 
Based on this information, HPV infection could modify host immune response and 
subsequently predict response to immunotherapy, which is currently a treatment 
modality in certain subgroups of lung cancer patients. Similarly, HPV infection 
appears to be associated with lung cancer in non-smokers, as are EGFR muta-
tions; therefore, it is possible that a synergistic approach could be reached when 
treating the infection in EGFR-mutated lung cancer patients who receive targeted 
agents. In this regard, a previous study by Li et al. demonstrated that the presence 
of HPV DNA was significantly associated with EGFR mutations in advanced lung 
ADC. Interestingly, patients with both HPV infections and EGFR mutations have 
a reduced risk of progression compared to those without HPV infection or EGFR 
mutation (adjusted HR = 0.640; 95% confidence interval: 0.488–0.840; P = 0.001), 
suggesting a prognostic role for HPV status in this patient subgroup [73]. Another 
likely suitable target for therapy is MEK, a mitogenic signaling pathway protein 
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activated as a result of KRAS mutations in HPV, and some anti-MEK therapies have 
been tested in lung cancer [100]. Pathophysiology of infection and main molecular 
pathways compromised are presented in Figure 3.
If lung cancer patients with HPV infection need to de-escalate treatment, as in 
head and neck cancer patients, they requires further investigation. Some arguments 
are in favor of de-escalation considering, for example, the fact that lung cancer 
patients with HPV infection seem to have a better prognosis. Wang et al. described 
ADC with HPV 16/18 infections as having significantly higher survival rates 
compared to those that are HPV16/18 negative [101]. In a similar way, Hsu et al. 
reported survival benefits for stage I NSCLC patients who expressed the HPV16/18 
E6 oncoprotein [102].
7. Conclusion
In conclusion, HPV infection constitutes a risk factor for lung cancer develop-
ment, especially in patients infected with high-risk serotypes 16 and 18, non-
smokers and females. HPV vaccination could have a potential role in the prevention 
of development of HPV-associated lung cancer. Furthermore, HPV status could 
modify some lung cancer treatment decisions; however, more information is 
needed to draw definitive conclusions.
8. Future perspectives
Future work in this field will likely include the validation of a screening test for 
HPV infection in lung cancer patients and also a strategy to follow HPV-infected 
individuals who might be at a higher risk of developing lung cancer. Additionally, 
the potential efficacy of anti-HPV vaccination for reducing the incidence of lung 
cancer must be adequately explored.
Figure 3. 
Pathophysiology of HPV infection and development of lung cancer.
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